GlassScriptPhysician profile
Dana A Andersen
NPI 1578595724
$3,526.21
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $1,207 · 2021: $515 · 2023: $50.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $524.39 | 2019-2021 | |
| Novo Nordisk INC | $412.45 | 2019-2021 | |
| Pfizer INC. | $378.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $229.32 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $177.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $173.29 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $129.19 | 2019 | |
| Lilly USA, LLC | $129.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $123.04 | 2019-2020 | |
| Abbvie INC. | $103.38 | 2020-2021 | |
| Allergan, INC. | $103.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.85 | 2019-2021 | |
| Daiichi Sankyo INC. | $89.05 | 2020-2021 | |
| Astellas Pharma US INC | $75.68 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $61.81 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.64 | 2019-2020 | |
| Gilead Sciences, INC. | $51.45 | 2019-2020 | |
| Abiomed | $50.82 | 2023 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.38 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $39.19 | 2019 | |
| Sanofi Pasteur INC. | $36.05 | 2019 | |
| Upsher-Smith Laboratories LLC | $33.69 | 2020-2021 | |
| Dynavax Technologies Corporation | $28.52 | 2019-2020 | |
| Cranial Technologies, INC | $28.24 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.34 | 2019-2020 | |
| Edwards Lifesciences Corporation | $23.47 | 2019 | |
| Antares Pharma, INC. | $20.76 | 2019 | |
| Shire North American Group INC | $12.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2020 | |
| Eisai INC. | $12.20 | 2020 | |
| Janssen Biotech, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.